<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449149</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01310</org_study_id>
    <nct_id>NCT01449149</nct_id>
  </id_info>
  <brief_title>Proton Radiation for Chordomas and Chondrosarcomas</brief_title>
  <official_title>Proton Radiation For Chordomas and Chondrosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are 1) To evaluate the feasibility and acute side effects of
      proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and
      long term side effects of proton beam radiation for treatment of chordomas and
      chondrosarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be conducted in two phases: a feasibility then a phase II trial. Once
      feasibility and safety are established in the first 12 pts. the phase II study will begin.
      Proton therapy at standard doses is not known to improve clinical outcome but will likely
      reduce fatigue and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>patient is unable to complete all of his/her treatments with 10 days of estimated date of treatment completion or requires a treatment breaks greater than 5 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>Any grade 3 or higher toxicty observed within 90 days from start of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>Any grade 3 or higher toxicty observed later than 90 days from completion of therapy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chordomas</condition>
  <condition>Chondrosarcomas</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of chordoma or chondrosarcoma.

          -  Patients must have no evidence of metastatic disease based on routine imaging (CT or
             MRI of the chest/abdomen/pelvis, bone scan, etc.)

          -  Patients must have an ECOG score equal to or less than 2.

          -  Age ≥ 18 years.

          -  Patients must be able to provide informed consent.

          -  Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3

          -  Women of child-bearing potential as long as she agrees to use a recognized method of
             birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.)
             Hysterectomy or menopause must be clinically documented.

          -  Tumors arising in the skull and spine.

        Exclusion Criteria:

          -  Prior or simultaneous malignancies within the past two years (other than cutaneous
             squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)

          -  Patients with the following histologies are excluded: melanoma , other soft tissue or
             bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other
             histologies.

          -  Pregnant women.

          -  Actively being treated on any other therapeutic research study.

          -  Tumors arising outside of the CNS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Alonso-Basanta, MD, PhD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Alonso-Basanta, MD, PhD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Michelle Alonso-Basanta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age 18 or greater</keyword>
  <keyword>No prior radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

